Medpace Holdings Inc
$ 590.67
0.97%
07 Aug - close price
- Market Cap 16,328,599,000 USD
- Current Price $ 590.67
- High / Low $ 594.99 / 582.08
- Stock P/E 34.60
- Book Value 15.54
- EPS 16.91
- Next Earning Report 2026-10-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.20 %
- ROE 1.62 %
- 52 Week High 677.90
- 52 Week Low 373.00
About
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Analyst Target Price
$581.83
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-22 | 2026-04-22 | 2026-02-09 | 2025-10-22 | 2025-07-21 | 2025-04-21 | 2025-02-10 | 2024-10-21 | 2024-07-22 | 2024-04-22 | 2024-02-12 | 2023-10-23 |
| Reported EPS | 4.25 | 4.28 | 4.67 | 3.86 | 3.1 | 3.67 | 3.6813 | 3.01 | 2.76 | 3.22 | 2.46 | 2.24 |
| Estimated EPS | 4.08 | 3.96 | 4.18 | 3.57 | 3 | 3.07 | 3.1167 | 2.87 | 2.63 | 2.49 | 2.22 | 2.19 |
| Surprise | 0.17 | 0.32 | 0.49 | 0.29 | 0.1 | 0.6 | 0.5646 | 0.14 | 0.13 | 0.73 | 0.24 | 0.05 |
| Surprise Percentage | 4.1667% | 8.0808% | 11.7225% | 8.1232% | 3.3333% | 19.544% | 18.1153% | 4.878% | 4.943% | 29.3173% | 10.8108% | 2.2831% |
Next Quarterly Earnings
| Sep 2026 | |
|---|---|
| Reported Date | 2026-10-19 |
| Fiscal Date Ending | 2026-09-30 |
| Estimated EPS | 4.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MEDP
2026-08-06 11:02:00
Medpace Holdings, Inc. (MEDP) exhibits compelling growth with double-digit earnings, strong profitability, and improving bookings, along with a significant pipeline for 2027. However, its valuation is considerably higher than industry and market averages. While the company's operational quality is high, the premium valuation and potential for uneven booking visibility suggest a selective approach rather than aggressive buying.
2026-08-05 18:40:21
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ:MEDP) securities. The investigation concerns whether Medpace and its officers/directors engaged in corporate wrongdoing, particularly for investors who purchased shares before April 22, 2025, and still hold them. The firm encourages affected shareholders to contact them for more information and to assist in the investigation at no cost, as they operate on a contingency fee basis.
2026-08-03 18:40:27
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ:MEDP) who bought securities prior to April 22, 2025, and still hold them. The investigation aims to determine if Medpace and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, offering their services on a contingency fee basis.
2026-08-01 03:11:16
Medpace Holdings (NASDAQ: MEDP) insiders have been selling stock, with the CEO selling $62 million worth and another insider selling $4.5 million recently. While insider ownership remains significant at 20% ($3.2 billion), the lack of insider buying and recent sales at current price levels raise some caution, despite the company being profitable and growing.
2026-07-31 13:07:55
Recent insider transactions at Medpace Holdings, Inc. revealed that an insider sold US$4.5 million worth of shares, reducing their holding by 11%. Over the last year, the CEO also sold US$62 million worth of shares at a price close to the current share price. While there have been no insider purchases, the company maintains high insider ownership and is profitable and growing.
2026-07-31 05:41:15
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Medpace Holdings, Inc. (NASDAQ: MEDP) investors who purchased securities before April 22, 2025, concerning alleged corporate wrongdoing by the company's officers and/or directors. The firm encourages affected stockholders to contact them for more information and to assist in the investigation, noting that they operate on a contingency fee basis. This investigation aims to restore investor capital and ensure corporate accountability.
